Please assess the completion status of the following clinical trial:

Trial Title: Low Dose Primaquine for Clearance of Gametocytes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2/PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Age \> 2 years and \<15 years~2. Weight over 10kg~3. P. falciparum parasitaemia \>1,000 parasites and \<200,000 parasites/µl~4. P. falciparum gametocytes detected by microscopy~5. Normal G6PD enzyme function~6. Informed consent by legally acceptable representative~Exclusion Criteria:~1. Enrolled in another study~2. Fever or history of fever in the last 24 hours~3. Evidence of severe illness/ danger signs~4. Known allergy to study medications~5. Hb \< 8g/dL~6. Started menstruation~7. Pregnancy or breastfeeding~8. Antimalarials taken within the last 2 days~9. Primaquine taken within the last 4 weeks~10. Blood transfusion within the last 90 days~11. Non-falciparum malaria co-infection

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 15 Years
- Healthy Volunteers: t

Study Arms:
- Artemether-Lumefantrine (Type: ACTIVE_COMPARATOR): Artemether-Lumefantrine combination
- Artemether-Lumefantrine-Primaquine 0.25 (Type: EXPERIMENTAL): Artemether-Lumefantrine with a single dose of 0.25mg/kg primaquine
- Artemether-Lumefantrine-Primaquine 0.4 (Type: EXPERIMENTAL): Artemether-Lumefantrine with a single dose of 0.4mg/kg primaquine

Based on this trial design, predict the completion outcome and termination type (if applicable).